IMUX

Immunic, Inc.

1.11 USD
+0.01 (+0.91%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Immunic, Inc. stock is down -11.2% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 54.55% of the previous 10 June’s closed higher than May.

About Immunic, Inc.

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease.